Rheumatoid arthritis

Trexject gets the tick from PBAC second time around

The Pharmaceutical Benefits Advisory Committee has approved pre-filled syringes for subcutaneous administration of methotrexate (Trexject) for the treatment of rheumatoid arthritis when oral methotrexate is unsuitable. The approval at their March meeting overturns a 2016 decision rejecting the application due to concerns about cost minimisation with the 50mg vial of methotrexate. However the latest decision ...

Already a member?

Login to keep reading.

© 2021 the limbic